Contact informationPlease contact Håvard E. Greger Danielsen for more information
Colorectal cancer (CRC) is the fourth most common cause of cancer-related death worldwide.
The total number is not known, but approximately 650.000 new cases are registered each year in industrialized countries. This represents a major burden for the patients affected and a huge cost to society. Five percent of all men and four percent of all women will be diagnosed with colorectal cancer before the age of 75. There has been a steady rise in the numbers in the last decades, which in large part is due to the increased life expectancy. There is a considerable demand for quality prognostic markers, which we aim to establish.
Stages of colorectal cancer
The colon/rectum consists of:
- ascending colon with appendix
- transverse colon
- descending colon
- sigmoid colon
Materials and Collaborations
The ICGI has procured several international collaborations, which allows us access to large sets of tumor material and clinical data.
University of Oxford and University College London:
- The Victor Trial: 822 patients surgically treated for cancer in stage 2 or 3
- The Quasar2 Trial: 1.283 patients surgically treated for cancer in stage 2 or 3
University of Gloucester, Cheltenham General Hospital and University College London:
- 1.042 consecutive patients surgically treated for cancer in stage 1-3, and not given any adjuvant chemotherapy (1988-1996.)
- 952 consecutive patients operated for all stages of colorectal cancer in the period between 1993-2003.
DNA ploidy analyses of tumors from the 952 patients from Aker demonstrated that ploidy is an independent prognostic marker for CRC. The size of the patient group made these studies statistically strong, and demonstrated an increased value of the ploidy marker in the subgroup of patients with stage II colorectal cancer.
ref.: Hveem TS et al., Prognostic impact of genomic instability in colorectal cancer. Br J Cancer, 110 (8), 2159-64, Pubmed: 24642618
We are in the process of analyzing a collection of tumor tissue from nearly 4.000 patients together with our international partners in the CRC Network. With such a large patient group we expect to further improve the methods that have had valuable results so far, and establish new markers based on digital imaging and Big Data analysis.
ref.: Enric Domingo et al., Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.J Pathol. 2013 Feb;229(3):441-8. doi: 10.1002/path.4139. Pubmed 23165447
ref.: Dmitri Mouradov et al., Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations.Am J Gastroenterol. 2013 Nov;108(11):1785-93. doi: 10.1038/ajg.2013.292. Pubmed 24042191
Institute Director Håvard E. Danielsen serves as chair of the panel of expertise for the CRC Network, which is an international network of researchers aiming to improve diagnosis, research and medical treatment of colon- and rectum cancer with emphasis on increased understanding of genetic mechanisms. The panel of expertise includes representatives from some of the highest-ranked universities in Europe.
Read more about the CRC Netwok on their website.
This text was last modified: 15.03.2017